# US 8,541,433 B2 · Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,433 B2
- Document ID: US8541433B2
- Status: Granted
- Kind: B2
- Application number: 12/867,939
- Filed: 2009-02-19
- Published: 2010-12-09
- Granted: 2013-09-24
- Earliest claimed: 2008-02-20
- Assignees: Actelion Pharmaceuticals Ltd.
- Applicants: Martine Clozel; Urs Regenass
- Inventors: Martine Clozel; Urs Regenass
- Web page: https://patentgrep.com/patent/US8541433B2

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.

## Claims

### Claim 1

A. method for the treatment of multi-drug resistant ovarian cancer, comprising administering, simultaneously, separately or over a period of time, to a patient in need thereof, a compound of formula (I):
in free or pharmaceutically acceptable salt form, in combination with paclitaxel, in free or pharmaceutically acceptable salt form.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) in free or pharmaceutically acceptable salt form is administered by intravenous or intraperitoneal route.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) in free or pharmaceutically acceptable salt form is administered by oral route.

### Claim 4 (depends on 1)

The method according to claim 1, wherein paclitaxel in free or pharmaceutically acceptable salt form is administered by intravenous or intraperitoneal route.